Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
26.64
+1.60 (6.39%)
At close: Apr 17, 2026, 4:00 PM EDT
27.54
+0.90 (3.38%)
After-hours: Apr 17, 2026, 7:10 PM EDT
Tango Therapeutics Employees
Tango Therapeutics had 137 employees as of December 31, 2025. The number of employees decreased by 18 or -11.61% compared to the previous year.
Employees
137
Change (1Y)
-18
Growth (1Y)
-11.61%
Revenue / Employee
$455,358
Profits / Employee
-$741,562
Market Cap
3.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 137 | -18 | -11.61% |
| Dec 31, 2024 | 155 | 15 | 10.71% |
| Dec 31, 2023 | 140 | 30 | 27.27% |
| Dec 31, 2022 | 110 | 19 | 20.88% |
| Sep 30, 2022 | 109 | 26 | 31.33% |
| Jun 30, 2022 | 103 | 17 | 19.77% |
| Mar 31, 2022 | 98 | 21 | 27.27% |
| Dec 31, 2021 | 91 | 14 | 18.18% |
| Sep 30, 2021 | 83 | 6 | 7.79% |
| Jun 30, 2021 | 86 | - | - |
| Mar 31, 2021 | 77 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| Dyne Therapeutics | 258 |
| Structure Therapeutics | 220 |
| Edgewise Therapeutics | 146 |
TNGX News
- 4 days ago - Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - GlobeNewsWire
- 3 months ago - Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - GlobeNewsWire
- 3 months ago - Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewsWire
- 4 months ago - Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 6 months ago - Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement - Benzinga
- 6 months ago - Tango Therapeutics Announces $225 Million Financing - GlobeNewsWire
- 6 months ago - Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 - GlobeNewsWire